CSAN3 reports Q1 2026 results today against one of its toughest price backdrops in recent memory. The stock has shed 16% over the past month and nearly 11% in the past week alone, arriving at BRL 4.65 — well below the analyst consensus target of BRL 7.48. That gap is wide enough to be notable: the Street collectively sees roughly 60% upside from current levels, though the consensus is dated to mid-March and no recent analyst activity has emerged to update it.
The sharpest story heading into this print is insider selling. Board members offloaded shares steadily through December 2025 — nine separate transactions spread across two weeks at prices between BRL 6.29 and BRL 6.61, totalling around $1.4 million in aggregate value. The executive board followed in March with two further block sales at BRL 5.97. Net insider activity over the past 90 days adds up to roughly 1.9 million shares sold for approximately $2.1 million in proceeds. That pattern of consistent, unhurried selling — not a single purchase on record — lends the price decline a more uncomfortable tone. Directors were trimming at prices well above where the stock now trades.
The lending market tells a different story, and a calmer one. Borrow availability is essentially wide open: cost to borrow is near a historical floor at 0.35%, and borrow demand has been negligible — utilisation has not registered above zero for the entire past month, with even its 52-week peak reaching only 14.4%. There is no meaningful short-side pressure in the lending market. Whatever is driving the sell-off, it is not driven by an organised short case. The ORTEX short score of 24.9 — low on a 0-100 scale — confirms this: short sellers are not piling in.
The ownership picture adds a layer of structural complexity. Vertiz Holding trimmed its stake dramatically in the last reported period, cutting by 490 million shares to hold 24.2% of the company. BTG Pactual's local asset management arm, by contrast, entered as a new holder with 8.4% of shares outstanding. Norges Bank and Vanguard both added modestly. The churn at the top of the register — a cornerstone holder reducing sharply while a major domestic institution builds a meaningful new position — suggests differing views on Cosan's conglomerate structure and its ability to manage leverage across subsidiaries including Rumo and Compass. Compass's recent $650 million IPO attempt made news earlier this month, representing a potential catalyst for unlocking value trapped in the holding company structure.
The Q1 results — EPS of -$0.31, improved from -$0.66 a year ago, on revenues of $1.715 billion — are already in the market. At a PE of 4.5x and EV/EBITDA near 3.5x, valuation multiples look compressed. The print will test whether the improving loss trajectory and subsidiary newsflow are enough to reverse a holder base that has been voting with its feet.
See the live data behind this article on ORTEX.
Open CSAN3 on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
